Natural Product: ENC001426

NPs Basic Information

Download MOL File
Name
Piperine
Molecular Formula C17H19NO3
IUPAC Name*
(2E,4E)-5-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylpenta-2,4-dien-1-one
SMILES
C1CCN(CC1)C(=O)/C=C/C=C/C2=CC3=C(C=C2)OCO3
InChI
InChI=1S/C17H19NO3/c19-17(18-10-4-1-5-11-18)7-3-2-6-14-8-9-15-16(12-14)21-13-20-15/h2-3,6-9,12H,1,4-5,10-11,13H2/b6-2+,7-3+
InChIKey
MXXWOMGUGJBKIW-YPCIICBESA-N
Synonyms
piperine; 94-62-2; 1-Piperoylpiperidine; Bioperine; Piperin; 7780-20-3; FEMA No. 2909; (E,E)-1-piperoylpiperidine; (2E,4E)-5-(benzo[d][1,3]dioxol-5-yl)-1-(piperidin-1-yl)penta-2,4-dien-1-one; N-[(E,E)-Piperoyl]piperidine; AI 3-01439; Piperidine, 1-piperoyl-, (E,E)-; piperidine, 1-[(2E,4E)-5-(1,3-benzodioxol-5-yl)-1-oxo-2,4-pentadienyl]-; (2E,4E)-5-(2H-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)penta-2,4-dien-1-one; NSC-21727; 1-[(2E,4E)-5-(1,3-benzodioxol-5-yl)penta-2,4-dienoyl]piperidine; (2E,4E)-5-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylpenta-2,4-dien-1-one; N-(E,E)-piperoyl-piperidine; CHEMBL43185; U71XL721QK; CHEBI:28821; NSC21727; Piperoylpiperidine; Piperidine, 1-(5-(1,3-benzodioxol-5-yl)-1-oxo-2,4-pentadienyl)-, (E,E)-; Piperidine, 1-[5-(1,3-benzodioxol-5-yl)-1-oxo-2,4-pentadienyl]-, (E,E)-; DSSTox_CID_1805; Piperidine, 1-(5-(3,4-methylenedioxyphenyl)-1-oxo-2,4-pentadienyl)-; 1-[(2E,4E)-5-(1,3-benzodioxol-5-yl)-1-oxo-2,4-pentadienyl]piperidine; DSSTox_RID_76339; DSSTox_GSID_21805; 1-[(2E,4E)-5-(1,3-Benzodioxol-5-yl)-2,4-pentadienoyl]piperidine; 5-(Benzo[d][1,3]dioxol-5-yl)-1-(piperidin-1-yl)penta-2,4-dien-1-one; Piperidine, 1-((2E,4E)-5-(1,3-benzodioxol-5-yl)-1-oxo-2,4-pentadienyl)-; Piperine [USP]; SMR000112278; CCRIS 5572; Piperine (aliphatic); 1-Piperoylpiperidine, (E,E)-; SR-01000638580; Piperidine, 1-piperoyl-; EINECS 202-348-0; NSC 21727; UNII-U71XL721QK; (2E,4E)-5-(1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)penta-2,4-dien-1-one; CAS-94-62-2; Piperine,(S); 1-Piperylpiperidine; Prestwick_398; MFCD00005839; 1,3-Benzodioxol-5-yl-1-oxo-2,4-pentadienyl-piperine; 1-Piperoyl-piperidine; NSC 242267; Piperine, >=97%; ST079380; starbld0008505; Piperidine, (E,E)-; PIPERINE [FHFI]; PIPERINE [INCI]; AI3-01439; PIPERINE [MI]; Prestwick2_000474; Prestwick3_000474; Spectrum5_001507; PIPERINE [USP-RS]; PIPERINE [WHO-DD]; 1-(5-(1,3-Benzodioxol-5-yl)-1-oxo-2,4-pentadienyl)piperidine, (E,E)-; Piperine, >=97%, FG; SCHEMBL94058; SCHEMBL94059; BSPBio_000608; BSPBio_002515; Piperine, analytical standard; MLS002153830; MLS002473213; BIDD:ER0675; SPECTRUM1500873; BPBio1_000670; GTPL2489; N-EE-PIPEROYL-PIPERIDINE; DTXSID3021805; Piperine (1-Piperoylpiperidine); CHEBI:93043; FEMA 2909; HMS502P16; 2,4-Pentadien-1-one, 5-(1,3-benzodioxol-5-yl)-1-(1-piperidinyl)-, (2E,4E)-; HMS1569O10; HMS1921M12; HMS2092M22; HMS2096O10; HMS2270M18; Pharmakon1600-01500873; 1-trans,trans-piperinoyl-piperidine; AMY40672; BCP18901; HY-N0144; ZINC1529772; Tox21_201990; Tox21_302746; 1-(5-(3,4-Methylenedioxyphenyl)-1-oxo-2,4-pentadienyl)piperidine; 1-PIPEROYL-(E,E)-PIPERIDINE; BBL027541; BDBM50148573; CCG-39991; NSC757803; s2344; STL377909; (2E,4E)-5-(1,3-benzodioxol-5-yl)-1-(1-piperidyl)penta-2,4-dien-1-one; AKOS003369047; CS-6155; DB12582; NSC-757803; SDCCGMLS-0066693.P001; IDI1_000954; (piperidin-1-yl)penta-2,4-dien-1-one; NCGC00094872-01; NCGC00094872-02; NCGC00094872-03; NCGC00094872-04; NCGC00094872-05; NCGC00094872-06; NCGC00094872-09; NCGC00256392-01; NCGC00259539-01; AC-11746; AS-17442; LS-14576; SBI-0051621.P002; CS-0368434; P0460; SW196642-2; EN300-20100; C03882; P-6920; AB00052185_08; EN300-7392817; AG-205/01792022; Q414501; (2E,4E)-5-(benzo[d][1,3]dioxol-5-yl)-1-; SR-01000638580-1; SR-01000638580-2; SR-01000638580-5; SR-01000638580-6; BRD-K59522102-001-08-8; PIPERINE (CONSTITUENT OF BLACK PEPPER) [DSC]; Q27164772; 1,3-Benzodioxol-5-yl-1-oxo-2,4-pentadienyl-piperidine; Piperine, European Pharmacopoeia (EP) Reference Standard; Z104476830; 1-[5-(1,3-Benzodioxol-5-yl)-2,4-pentadienoyl]piperidine; 4-(1,3-Benzodioxole-5-yl)-1,3-butenylpiperidino ketone; Piperine, United States Pharmacopeia (USP) Reference Standard; 5-(1,3-benzodioxol-5-yl)-1-(1-piperidinyl)-1-penta-2,4-dienone; 5-(1,3-dioxaindan-5-yl)-1-(piperidin-1-yl)penta-2,4-dien-1-one; Piperidine,3-benzodioxol-5-yl)-1-oxo-2,4-pentadienyl]-, (E,E)-; (E,E) 1-[5-(1,3-benzodioxol-5-yl)-1-oxo-2,4-pentadienyl]piperidine; (E,E)-1-(5-(1,3-BENZODIOXOL-5-YL)-2,4-PENTADIENOYL)PIPERIDINE; 1-[(2E,4E)-5-(1,3-Benzodioxol-5-yl)-2,4-pentadienoyl]piperidine #; (2E,4E)-5-(1,3-dioxaindan-5-yl)-1-(piperidin-1-yl)penta-2,4-dien-1-one; 147030-08-8
CAS 94-62-2
PubChem CID 638024
ChEMBL ID CHEMBL43185
*Note: the IUPAC Name was collected from PubChem.
Chemical Classification:
  • Kingdom: Organic compounds
    • Superclass: Alkaloids and derivatives
      • Class: No Rank at Level Class
        • Subclass: No Rank at Level Subclass
          • Direct Parent: Alkaloids and derivatives

ClassyFire Version 1.0
PMID:27867422

NPs Species Source

Endophyte ID Endophyte Name Family Genus Taxonomy ID GenBank ID Closest GenBank ID Reference
Endophyte ID Endophyte Name Family Genus Taxonomy ID GenBank ID Closest GenBank ID Reference

NPs Content

*Note: The vaules in Content Percentage are calculated by dividing the content value by the maximum content value in NP Content.
**Note: The units with different NP content, due to their incomparable values, are separated into different tables.

NPs Biological Activity

Bioactivity Name Target ID Target Name Target Type Target Organism Target Organism ID Potency of Bioactivity Activity Type Value Unit Endophyte ID Endophyte Name
Bioactivity Name Target ID Target Name Target Type Target Organism Target Organism ID Potency of Bioactivity Activity Type Value Unit Endophyte ID Endophyte Name

NPs Physi-Chem Properties

Molecular Weight: 285.34 ALogp: 3.5
HBD: 0 HBA: 3
Rotatable Bonds: 3 Lipinski's rule of five: Accepted
Polar Surface Area: 38.8 Aromatic Rings: 3
Heavy Atoms: 21 QED Weighted: 0.626

NPs ADMET Properties*

ADMET: Absorption

Caco-2 Permeability: -4.839 MDCK Permeability: 0.00003130
Pgp-inhibitor: 0.993 Pgp-substrate: 0.009
Human Intestinal Absorption (HIA): 0.003 20% Bioavailability (F20%): 0.2
30% Bioavailability (F30%): 0.007

ADMET: Distribution

Blood-Brain-Barrier Penetration (BBB): 0.715 Plasma Protein Binding (PPB): 95.12%
Volume Distribution (VD): 0.435 Fu: 4.62%

ADMET: Metabolism

CYP1A2-inhibitor: 0.985 CYP1A2-substrate: 0.241
CYP2C19-inhibitor: 0.94 CYP2C19-substrate: 0.195
CYP2C9-inhibitor: 0.536 CYP2C9-substrate: 0.949
CYP2D6-inhibitor: 0.923 CYP2D6-substrate: 0.912
CYP3A4-inhibitor: 0.936 CYP3A4-substrate: 0.193

ADMET: Excretion

Clearance (CL): 10.777 Half-life (T1/2): 0.313

ADMET: Toxicity

hERG Blockers: 0.856 Human Hepatotoxicity (H-HT): 0.121
Drug-inuced Liver Injury (DILI): 0.602 AMES Toxicity: 0.008
Rat Oral Acute Toxicity: 0.012 Maximum Recommended Daily Dose: 0.1
Skin Sensitization: 0.84 Carcinogencity: 0.853
Eye Corrosion: 0.068 Eye Irritation: 0.552
Respiratory Toxicity: 0.935
*Note: the ADMET properties was calculated by ADMETlab 2.0. Reference: PMID: 33893803.

Similar Compounds*

Compounds similar to EMNPD with top10 similarity:

Similar NPs Similar Drugs
NPs ID NPs 2D Structure Similarity Score TTD ID Drug 2D Structure Similarity Score
ENC005030 0.324 D02XSA 0.380
ENC001470 0.312 D0X0WU 0.270
ENC001881 0.295 D09FJB 0.260
ENC001440 0.244 D0O4EU 0.245
ENC000702 0.242 D0V9EN 0.244
ENC004624 0.241 D06GDY 0.243
ENC001453 0.239 D04QLR 0.242
ENC005523 0.235 D08VSI 0.238
ENC001101 0.235 D07UXP 0.237
ENC002601 0.231 D04NTJ 0.230
*Note: the compound similarity was calculated by RDKIT.